Activation of Beta-3 Adrenergic Receptors with the Selective Agonist Mirabegron Elicits Multi-Site Mechanical Hypersensitivity, Grimace, and Increased Interleukin-6 Levels in Mice
Mirabegron is an adrenergic receptor beta-3 (Adrb3) selective agonist that is currently FDA-approved for the treatment of overactive bladder, with common side effects including headache and multi-site body pain. Our prior work has demonstrated that catecholamine activation of Adrb3 leads to chronic primary pain (CPP) through increased secretion of interleukin-6 (IL-6) from adipocytes. Pain development is blocked by pharmacologic inhibition or genetic knockdown of Adrb3. We evaluated the effects of mirabegron on evoked and spontaneous measures of pain, and IL-6 production.
Source: The Journal of Pain - Category: Materials Science Authors: Jennifer Ricano, Jiegen Chen, Yaomin Wang, Andrea Nackley Source Type: research
More News: Chronic Pain | Genetics | Headache | Materials Science | Migraine | Overactive Bladder | Overactive Bladder Syndrome | Pain